PITTSBURGH--The University of Pittsburgh, through the research of investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD, has entered into a research agreement with Abbott Laboratories to develop novel cancer drugs that block the activity of the ras oncogene.
